Secreted follistatin isoform that binds activins and related TGF-beta ligands
PRODUCT PROFILE
Follistatin 344
£76.00
Follistatin 344 is secreted follistatin isoform that binds activins and related tgf-beta ligands. Researchers examine it in relation to myostatin/activin regulation, muscle biology and fibrosis pathways.
Why it is distinct
A ligand-binding inhibitor of the activin/myostatin system, not a GH or IGF secretagogue.
- Evidence stageExperimental
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
Follistatin 344 is secreted follistatin isoform that binds activins and related tgf-beta ligands. Researchers examine it in relation to myostatin/activin regulation, muscle biology and fibrosis pathways.
Research focus+
Researchers study how those signals regulate muscle growth, scarring and tissue development. It has powerful biological effects but little reliable evidence for consumer use.
How the mechanism differs+
Sequesters activin-family ligands, including myostatin, rather than directly activating a growth receptor.
Evidence and limitations+
Strong biological rationale and preclinical work; human research has focused more on gene-transfer strategies than unverified peptide vials.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study how those signals regulate muscle growth, scarring and tissue development. It has powerful biological effects but little reliable evidence for consumer use.
Sequesters activin-family ligands, including myostatin, rather than directly activating a growth receptor.
A ligand-binding inhibitor of the activin/myostatin system, not a GH or IGF secretagogue.
Strong biological rationale and preclinical work; human research has focused more on gene-transfer strategies than unverified peptide vials.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch file pendingShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Established
Sermorelin
£49.005 mgBatch file pendingClosest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
UnavailableAsk about availability -
Early human evidence
Hexarelin
£51.005 mgBatch file pendingA potent older GHRP with less hormonal selectivity than ipamorelin.
UnavailableAsk about availability -
Early human evidence
GHRP-2
£44.005 mgBatch file pendingTypically characterised as a strong GH secretagogue with less appetite emphasis than GHRP-6.
UnavailableAsk about availability